(Reuters) - The news about Avandia, also known as rosiglitazone, triggered a freefall in GSK's shares, which closed off more than 5 percent on the London Stock Exchange. The stock slide continued on the New York Stock Exchange, falling $3.67 per share, or more than 6 percent.
Glaxo said it strongly disagreed with the conclusions of the report, which was based on an analysis of other studies.
Read more at Reuters.com Business News
Glaxo said it strongly disagreed with the conclusions of the report, which was based on an analysis of other studies.
Read more at Reuters.com Business News
No comments:
Post a Comment